This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alcaraz, A. Articles by Jenkins, R. B. Search for Related Content PubMed PubMed Citation Articles by Alcaraz, A. Articles by Jenkins, R. B.

Aneuploidy and Aneusomy of Chromosome 7 Detected by Fluorescence in Situ Hybridization Are Markers of Poor Prognosis in Prostate Cancer¹

Department of Urology [A. A., S. T., J. A. B., M. M. L.], Laboratory Medicine and Pathology [J. F. H., R. B. J.], and Section of Biostatistics [E. J. B., J. J. L-K.], Mayo Clinic and Foundation, Rochester, Minnesota 55905

Fluorescence in situ hybridization is a new methodology which can be used to detect cytogenetic anomalies within interphase tumor cells. We used this technique to identify nonrandom numeric chromosomal alterations in tumor specimens from the poorest prognosis patients with pathological stages T₂N₀M₀ and T₃N₀M₀ prostate carcinomas. Among 1368 patients treated by radical prostatectomy, 25 study patients were ascertained who died most quickly from progressive prostate carcinoma within 3 years of diagnosis and surgery. Tumors from 25 control patients who survived for more than 5 years and who were matched for age, tumor histological grade, and pathological stage also were evaluated. The tumors from all 25 (100%) poor prognosis patients and from 11 of 25 (44%) control patients were found to be aneuploid by fluorescence in situ hybridization (P < 0.0001). Alterations of chromosome 7 were observed in 24 of the tumors (96%) from the poor prognosis patients versus 3 tumors (12%) from the control group (P < 0.0001). Moreover, a characteristic aneuploidy pattern with multiple abnormal chromosomes and a hypertetrasomic population was generally found in tumors from the poor prognosis patients. This preliminary study suggests that fluorescence in situ hybridization studies of prostate cancer specimens may help to identify those patients at highest risk for early cancer death.

¹ Supported in part by a grant from Imagenetics Inc., Naperville, IL (to R. B. J.); Grant CA 58225 from NIH (to R. B. J., M. M. L., S. T.); and by Grant FIS 93/5326 from the Hospital Clinic de Barcelona and Fondo de Investigaciones Sanitarias (to A. A.).

² To whom requests for reprints should be addressed, at Cytogenetics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Received 4/ 6/94. Accepted 6/14/94.

This article has been cited by other articles:

				R. M. Medeiros, A. Morais, A. Vasconcelos, S. Costa, D. Pinto, J. Oliveira, P. Ferreira, and C. Lopes Outcome in Prostate Cancer: Association with Endothelial Nitric Oxide Synthase Glu-Asp298 Polymorphism at Exon 7 Clin. Cancer Res., November 1, 2002; 8(11): 3433 - 3437. [Abstract] [Full Text] [PDF]

				J. C. Alers, P.-J. Krijtenburg, A. N. Vis, R. F. Hoedemaeker, M. F. Wildhagen, W. C. J. Hop, T. H. van der Kwast, F. H. Schroder, H. J. Tanke, and H. van Dekken Molecular Cytogenetic Analysis of Prostatic Adenocarcinomas from Screening Studies : Early Cancers May Contain Aggressive Genetic Features Am. J. Pathol., February 1, 2001; 158(2): 399 - 406. [Abstract] [Full Text] [PDF]

				C. Abate-Shen and M. M. Shen Molecular genetics of prostate cancer Genes & Dev., October 1, 2000; 14(19): 2410 - 2434. [Full Text]

				N. N. Nupponen, L. Kakkola, P. Koivisto, and T. Visakorpi Genetic Alterations in Hormone-Refractory Recurrent Prostate Carcinomas Am. J. Pathol., July 1, 1998; 153(1): 141 - 148. [Abstract] [Full Text] [PDF]